SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiotechnology
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (7)10/1/2000 7:30:07 PM
From: Mike McFarland  Read Replies (1) of 16
 
The addition of risperidone would appear to be a useful strategy for augmenting SRI effectiveness in refractory OCD patients.

Int Clin Psychopharmacol 2000 Sep;15(5):297-301
Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.

The Expert Consensus Guideline Series:
Treatment of Obsessive-Compulsive Disorder
psychguides.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News